Company Seeks to Import Ibogaine, MDMA, and Psilocybin
Published Date: 10/19/2026
Notice
Summary
Groff Health Inc. wants to become an official importer of some powerful controlled substances like Ibogaine, MDMA, and Psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by November 18, 2026. This move could shake up how these substances enter the U.S., so keep an eye on the deadlines and get ready to speak up if you’re affected!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer Application: Schedule I Bulk Supply
If you are a researcher, clinical trial sponsor, or a customer of Groff Health Inc., the company applied on August 7, 2026 to import bulk Schedule I substances — Ibogaine (code 7260), MDMA (code 7405), Psilocybin (code 7437), and Psilocyn (code 7438) — to support internal research, clinical trials, analytical purposes, and distribution to their customers. Public comments or requests for a hearing on the application must be submitted by November 18, 2026.
No Import of Finished Dosage Forms
The DEA says that any registration issued will not authorize Groff Health Inc. to import finished dosage forms (whether FDA-approved or not) for commercial sale. If you are a company that intended to import finished drug products of these substances for sale, this registration will not permit that activity.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-21413, Jefferson Burroughs, M.D.; Decision and Order
Dr. Jefferson Burroughs from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2026. This means Dr. Burroughs can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
2026-21414, Jan Pijanowski, M.D.; Decision and Order
Dr. Jan Pijanowski from Ohio lost his DEA registration because his medical license expired and he didn’t respond to the DEA’s notice. This means he can no longer prescribe or handle controlled substances, effective immediately. If you’re a patient or pharmacy, this change is official as of October 2026 and affects any prescriptions tied to him.
Previous / Next Documents
Previous: 2026-21354, Importer of Controlled Substances Application: DMS Pharmaceutical Group
DMS Pharmaceutical Group wants to become an official importer of fentanyl, a powerful controlled substance. People and companies involved with these drugs can share their thoughts or ask for a hearing by November 18, 2026. This move could impact how fentanyl is brought into the U.S., so keep an eye on the deadline if you’re involved!
Next: 2026-21357, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Services Surveys: BE-125, Quarterly Survey of Transactions in Selected Services and Intellectual Property With Foreign Persons
The Department of Commerce wants your thoughts on a survey that collects info from U.S. businesses dealing with foreign folks in services and intellectual property. If your sales with foreign partners hit $6 million or more, this affects you! They’re asking for comments by December 18, 2026, to keep the survey smooth and useful without wasting anyone’s time or money.